

Flash Note: UG Healthcare Corporation Limited

Date: 25 August 2017

Results Note

UG Healthcare Corporation Limited ("**UGHC**") reported Q4 FY17 results on 24 August 2017 after market close. Revenue for Q4 FY17 came in 22.5% higher on a year-on-year ("**y-y**") basis, though the significant increase in average raw materials prices, gas tariff hike, higher depreciation charge for the new production lines and the foreign workers' levy weighed on over profitability.


Fourth quarter results review

- <u>Revenue</u>: UGHC reported fourth quarter revenue that was 22.5% higher on a y-y basis. For the full year, UGHC reported an overall 10.9% increase in total revenues of S\$65 million for FY17. The higher revenue in the fourth quarter was mainly driven by the increase in the volume of gloves produced and sold at a slightly higher average selling price.
- 2. <u>Gross profit</u>: Despite the revenue increase, gross profit narrowed by 2.1% on the significant increase in raw materials prices, gas tariff hikes and the increase in labour costs as UGHC ramped up additional hiring in preparation for the additional capacity that is scheduled to come on-stream in March 2018. The result is that gross margins narrowed by about 400 basis points to 11.6%.
- 3. <u>Net profit attributable to owners:</u> Overall, net profit attributable to owners of the company declined by 43.5% owing to administrative expenses due to (i) the losses incurred by the UK subsidiary in hedging contracts, this is owing to the recent strengthening of the British pound against the US dollar, and (ii) the increase in general administrative running expenses from its expansion plans.
- 4. <u>Dividends</u>: No dividend has been proposed or declared by the Directors for the full year ended 30 June 2017 as the Group conserves cash for their expansion plans.

Expansion of Production Capacity

UGHC achieved a full year production capacity of 2.4 billion gloves at end-FY17, in-line with their plans. UGHC is on track in the execution of its expansion plans, and construction of a new production facility on an adjoining piece of land is underway, with commercialisation of the production lines expected by March 2018.

This is expected to increase annual production capacity by 500 million gloves per annum. The additional capacity will be progressively rolled out to achieve a total of 2.9 billion gloves in production capacity by end of FY2018.



Source: Company data, SAC Advisors

About UGHC

UGHC and together with its subsidiaries is an established natural latex and nitrile examination gloves manufacturer and distributor. Currently, the Group has two manufacturing facilities in Seremban, Malaysia. To complement this manufacturing platform, it has established an extensive distribution network globally through its own distribution companies based in the USA, UK, Germany, the PRC and Nigeria, as well as through third party distributors.

> Analyst Terence Chua +65 6221 5590 tchua@saccapital.com.sg



DISCLAIMERS AND DISCLOSURES

This report has been prepared and distributed by SAC Advisors Private Limited ("**SAC Advisors**") which is a holder of a capital markets services licence and an exempt financial adviser in Singapore. SAC Advisors is a wholly-owned subsidiary of SAC Capital Private Limited ("**SAC Capital**") which is also a capital markets services licensee.

This report has been prepared for the purpose of general circulation. In the preparation of this report, we have not had regard to the specific investment objectives, financial situation, tax position or unique needs and constraints of any individual person or any specific group of persons. Any prospective purchaser should make his own investigation of the securities and all information provided. Advice should be sought from a financial adviser regarding suitability, taking into account the specific investment objectives, financial situation or particular needs of the person in receipt of the recommendation, before a commitment to purchase is entered into.

This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities.

This report is confidential and is meant only for the consumption of targeted persons. The information in this report shall not be copied or reproduced in part or in whole, and save for the recipient of this report, shall not be disclosed to any other person without the prior written consent of SAC Advisors. The distribution of this report outside the jurisdiction of Singapore is also strictly prohibited.

While SAC Advisors has exercised reasonable care to ensure that the facts stated herein are accurate, SAC Advisors makes no representation as to the accuracy or completeness of such information and SAC Advisors accepts no liability whatsoever for any loss or damage arising from the use of or reliance of the information herein.

SAC Advisors, SAC Capital and their associates, directors, and/or employees may have positions in the securities covered in the report and may also perform or seek to perform other corporate finance related services for the company whose securities are covered in the report. SAC Advisors and its related companies may from time to time perform advisory services, or solicit such advisory service from the entity mentioned in this report ("**Other Services**"). However, the research professionals involved in the preparation of this report have not and will not participate in the solicitation of such business. This report is therefore classified as a non-independent report.

As of the date of this report, SAC Advisors and its associates, including SAC Capital, do not have proprietary positions with UG Healthcare Corporation Limited, except for:

Party	Quantum of position
Nil	Nil

As of the date of this report, SAC Advisors and its associates, including SAC Capital, do not have any business relations with UG Healthcare Corporation Limited within the past 12 months, except for:

Company	Nature of business relation	Date of business relation
UG Healthcare Corporation Limited	Continuing Sponsor	Ongoing



As of the date of this report, none of the analysts who covered the securities in this report have any proprietary position or material interest in the subject companies covered here in, except for:

Analyst name	Quantum of position
Nil	Nil

ANALYST CERTIFICATION/REGULATION AC

As noted above, research analyst(s) of SAC Advisors who produced this report hereby certify that

(i) The views expressed in this report accurately reflect his/her personal views about the subject corporation(s);

(ii) The report was produced independently by him/her;

(iii) He/she does not on behalf of SAC Advisors or SAC Capital or any other person carry out Other Services involving any of the subject corporation(s) or securities referred to in this report; and

(iv) He/she has not received and will not receive any compensation directly or indirectly related to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. He/she has not and will not receive any compensation directly or indirectly linked to the performance of the securities of the subject corporation(s) from the time of the publication of this report either.